Determination of systemic inflamatory biomarkers in multiple sclerosis
Abstract
Background: Multiple sclerosis is one of the most common demyelinating diseases of the central nervous system. We aimed to investigate serum and cerebrospinal fluid levels of different laboratory inflammatory biomarkers in patients with MS.
Methods: A total of 120 subjects participated in the study, 60 of whom are diagnosed with MS, 30 with the final diagnose of non-inflammatory diseases of the CNS, and 30 healthy subjects representing the control group. Regarding to progression of radiological findings after 2 years from the initial diagnosis, MS group was divided into subgroups: with stationary radiological findings (n=30) and with radiologically proven disease progression (n=30). In all patients we analyzed levels of laboratory inflammatory biomarkers: CRP, NLR, GDF15 and NFs. Values of NFs and GDF15 were analyzed initial while the values of CRP and NLR were analyzed initial and after two years.
Results: We found statistically lower GDF15 values and initial CRP values in MS group in regards to group with non-inflammatory diseases of the CNS (p=0.000). On the other side, we determined significant elevation of laboratory markers CRP and NLR, initial and after two years period, in MS subgroup with progression of MRI findings (p= 0.000 and p=0.050, respectively). Also we found a positive correlation of CRP and neurofilaments (r=0.243, p=0.04), as well as a positive correlation of CRP and GDF15 in patients with MS (r=0.769, p=0.000).
Conclusion: We found significant elevation of laboratory markers of systemic inflammation, CRP and NLR in MS patients who developed disease progression based on MRI findings.
Key words: Multiple sclerosis; Neutrophil to lymphocyte ratio; C reactive protein, Neurofilaments, Growth differentiation factor 15
Copyright (c) 2023 Maša Todorović, Stanislava Nikolić, Željko Živanović, Svetlana Simić, Lorand Sakalaš, Igor Spasić, Branislava Ilinčić, Velibor Čabarkapa
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.